Cell Viability Assay Kit, BioAssay(TM)

The study of cell proliferation and cell viability requires the accurate quantification of the number of viable cells in a cell culture. Therefore, assays for calculating cell viability are necessary for optimizing cell culture conditions, evaluating cell growth factors and nutrients, discovering novel antibiotics and anti-cancer drugs, evaluating toxic effects of environmental pollutants and cell mediated toxicity and studying programmed cell death (apoptosis).\nThe Cell Viability assay kit provides a convenient, sensitive, quantitative and reliable assay for determining the number of viable cells in a given culture. This homogeneous Colorimetric Assay: is based on the conversion of a tetrazolium salt MTT, a pale yellow substrate, to formazan, a purple dye. This cellular reduction reaction involves the pyridine nucleotide cofactors NADH/NADPH and is only catalyzed by living cells. The formazan product has a low aqueous solubility and is present as purple crystals. Dissolving the resulting formazan with a solubilization buffer permits the convenient quantification of product formation. The intensity of the product color, measured at 550-620 nm, is directly proportional to the number of living cells in the culture. Reagents in the kit have been carefully formulated and optimized for sensitivity, assay robustness and automation.\n\nKey Features:\nSafe. Non-radioactive assay (cf. 3H-thymidine incorporation assay).\nSensitive and accurate. As low as 950 cells can be accurately quantified.\nFast. High-throughput assay using 96-well plates allows simultaneous processing tens of thousands of samples per day.\nHomogeneous and convenient. "Mix-incubate-measure" type assay. No wash and reagent transfer steps are involved.\nRobust and amenable to HTS. Z

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C2609-24

Size

1Kit

References

1. Luan X, Diekwisch TG (2002). CP27 affects viability, proliferation, attachment and gene expression in embryonic fibroblasts. Cell Prolif. 35: 207-19.\n2. Bezivin C, Tomasi S, Lohezic-Le Devehat F, Boustie J (2003). Cytotoxic activity of some lichen extracts on murine and human cancer cell lines. Phytomedicine. 10(6-7): 499-503.\n3. Koh J, Kubota T, Koyama T, Migita T, Hashimoto M, Hosoda Y, Kitajima M (2000). Combined Antitumor Activity of 7-Hydroxystaurosporine (UCN-01) and Tamoxifen against Human Breast Carcinoma in vitro and in vivo. Breast Cancer. 10(3): 260-7.\n4. Labieniec M, Gabryelak T (2003). Effects of tannins on Chinese hamster cell line B14. Mutat Res. 539(1-2): 127-35.\n5. Camps J, About I (2003). Cytotoxicity testing of endodontic sealers: a new method. J Endod. 29(9): 583-6.\n6. Di Francesco AM, Mayalarp SP, Kim S, Butler J, Lee M (2003). Synthesis and biological evaluation of novel diaziridinylquinone-acridine conjugates. Anticancer Drugs. 14(8): 601-15.\n7. Moongkarndi P, Kaslungka S, Kosem N, Junnu S, Jongsomboonkusol S, Theptaranon Y, Neungton N (2003). Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel. Asian Pac J Allergy Immunol. 21(1): 31-41.\n8. Yamashita T, Fujii M, Tomita T, Ishiguro R, Tashiro M, Tokumaru Y, Imanishi Y, Kanke M, Ogawa K, Kameyama K, Otani Y (2003). The inhibitory effect of matrix metalloproteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma. Anticancer Res. 23(3B): 2297-302.\n9. Nakamori M, Iwahashi M, Nakamura M, Yamaue H(2003). Clinical benefit of chemosensitivity test for patients with regional lymph node- positive esophageal squamous cell carcinoma. J Surg Oncol. 84(1): 10-6.\n10. Ariyoshi Y, Shimahara M, Tanigawa N(2003). Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol. 39(7): 701-7.\n11. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T, Fukushima M(2003). Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: A study of 88 surgical specimens. Cancer Sci. 94(7): 633-638.\n12. Tallen G, Riabowol K, Wolff JE(2003). Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. Anticancer Res. 23(2B): 1631-5.\n13. Nishimura S, Murasugi T, Kubo T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T, Nakagami Y(2003). RS-4252 inhibits amyloid beta-induced cytotoxicity in HeLa cells. Pharmacol Toxicol. 93(1): 29-32.\n14. Nakagami Y, Nishimura S, Murasugi T, Kubo T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T(2002). A novel compound RS- 0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro. Eur J Pharmacol. 457(1): 11-7.\n15. Wu J, Zhang H, Wang J, Yang T, Xian J, Yang C, Zheng W, Chen H, Wang Q(2002). Screening for inhibitor of vascular endothelial growth factor from random peptide library. Zhonghua Zhong Liu Za Zhi. 24(6): 540-3.\n16. Ren DC, Du GH, Zhang JT(2003). High throughput screening for intercellular adhesion molecule-1 inhibitor. Yao Xue Xue Bao. 38(6): 405-8.